论文部分内容阅读
目的:分析恩替卡韦单药与拉米夫定配伍阿德福韦酯对乙肝肝硬化的临床疗效情况。方法:选取我院80乙肝肝硬化患者行对照研究,按随机数字表将其分为实验组和对照组,每组各40例。对照组应用恩替卡韦;实验组应用拉米夫定配伍阿德福韦酯;对比两组HBV-DNA的阴转率及肝肾功能指标变化情况。结果:两组8周、12周HBV-DNA的阴转率比较,P>0.05,差异无统计学意义。经过一个月的治疗后,两组患者PTA、ALT及TBIL值均显著改善(P<0.05)。结论:采用拉米夫定配伍阿德福韦酯治疗乙肝肝硬化具有起效快,耐药率低的特点,其整体疗效与恩替卡韦相当。
Objective: To analyze the clinical efficacy of entecavir monotherapy combined with lamivudine adefovir dipivoxil on cirrhosis of hepatitis B. Methods: We selected 80 patients with hepatitis B cirrhosis in our control study, according to random number table divided into experimental group and control group, 40 cases in each group. The control group was entecavir. The experimental group was treated with lamivudine plus adefovir dipivoxil. The negative conversion rate of HBV-DNA and the changes of liver and kidney function were compared between the two groups. Results: There was no significant difference in the negative conversion rate of HBV-DNA between the two groups at 8 weeks and 12 weeks (P> 0.05). After a month of treatment, the PTA, ALT and TBIL values of both groups were significantly improved (P <0.05). Conclusion: Lamivudine combined adefovir dipivoxil treatment of hepatitis B cirrhosis with fast onset, low resistance rate, the overall efficacy of entecavir quite.